- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00449852
Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease (IVR)
April 27, 2011 updated by: Ottawa Heart Institute Research Corporation
An Interactive, Voice Response-Mediated, Follow-up and Triage System for Smoking Cessation in Smokers With Coronary Heart Disease
A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking.
The investigators hypothesize that compared to usual care, participants in the IVR group will; a) have a significantly higher 7-day point prevalence abstinence rate at 26 and 52 weeks after hospital discharge, b) will have a higher rate of continuous abstinence at 26 and 52 weeks after hospital discharge, c) will use a greater number of proven effective interventions over time, and d) will develop greater self-efficacy with respect to smoking cessation, over time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Quitting smoking appears to be the single most effective intervention or treatment to reduce mortality in patients with Coronary Heart Disease (CHD).
However, despite interventions, almost two-thirds of smokers resumed smoking in the year after hospitalization for CHD related illnesses; one-third resumed smoking within one month.
A critical challenge for institution-level programs is how to provide consistent patient follow-up and linkage to community-based smoking cessation resources.
Interactive voice response (IVR) technology has the potential to improve follow-up with smokers after hospitalization and to enhance triage to clinical support for smoking cessation.
IVR uses natural language to place automated out-going calls that can pose questions regarding smoking status and progress with smoking cessation, that is then dropped into a database.
A counselor is then able to link with the database and obtain information about the patient's smoking cessation needs and provide support as appropriate.
A randomized control trial (RCT) is planned to evaluate whether an IVR system for follow-up and triage helps smokers hospitalized for CHD, quit smoking over 26- and 52-week follow-up periods.
Participants are randomized into either a Usual Care or IVR group.
Both groups will receive in-patient counseling and offer of nicotine replacement therapy.
The IVR group will additionally receive a telephone call from the IVR system three, 14, 30, 60, 90, 120, and 150 days after hospital discharge.
Variables that will be assessed at 26 and 52 weeks include: smoking status, both 7-day point-prevalent and continuous abstinence, as well as self-efficacy for smoking cessation, use of effective cessation resources and patient satisfaction (at 26 weeks).
Study Type
Interventional
Enrollment (Actual)
442
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y4W
- University of Ottawa Heart Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is currently a smoker (greater than 5 cigarettes per day in the month preceding admission);
- Patient is 18 years of age and older;
- Patient is admitted to the in-patient cardiology service at the University of Ottawa Heart Institute (UOHI) for: a) Acute Coronary Syndrome (includes patients admitted for unstable angina or acute myocardial infarction), b) Elective Percutaneous Coronary Intervention (PCI), c) Coronary Artery Bypass Graft (CABG) or d) diagnostic catheterization procedures related to CHD;
- Patient has received automatic referral for smoking cessation counseling;
- Patient is willing to provide informed consent
Exclusion Criteria:
- Patient is unable to read and understand English;
- Patient lives more than 1.5 hours from UOHI;
- Patient is returning to referring institution/hospital
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interactive Voice Response Group
|
The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
|
|
No Intervention: Usual Care Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Biochemically confirmed 7-day point prevalent smoking abstinence
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Use of smoking cessation resources
Time Frame: 26 & 52 weeks
|
26 & 52 weeks
|
|
Self-efficacy in regards to smoking cessation
Time Frame: 26 & 52 weeks
|
26 & 52 weeks
|
|
Patient Satisfaction of the IVR system
Time Frame: 26 weeks
|
26 weeks
|
|
Continuous Abstinence since hospitalization
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Robert D Reid, PhD., University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre
- Principal Investigator: Andrew Pipe, C.M, MD, University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre
- Principal Investigator: Bonnie Quinlan, BSCN, University of Ottawa Heart Institute, Prevention and Rehabilitation Centre
- Principal Investigator: Heather Sherrard, BSCN, MHA, Ottawa Heart Institute Research Corporation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2006
Primary Completion (Actual)
February 1, 2011
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
March 19, 2007
First Submitted That Met QC Criteria
March 20, 2007
First Posted (Estimate)
March 21, 2007
Study Record Updates
Last Update Posted (Estimate)
April 29, 2011
Last Update Submitted That Met QC Criteria
April 27, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA 5845
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Infirmerie Protestante de LyonRecruitingCoronary Artery Bypass | Coronary Artery Disease(CAD) | Off Pump Coronary Artery Bypass Surgery | Hemodynamic Optimization | Hemodynamic Management | Off Pump Coronary Artery Bypass Graft | Coronary Artery Disease With Need for Bypass Surgery | NoradrenalineFrance
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCompletedCoronary Artery Disease (CAD) | Atherosclerosis of Coronary ArteryItaly
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
University Medical Centre LjubljanaRecruitingCoronary Artery Disease With Myocardial InfarctionSlovenia
-
Istanbul Mehmet Akif Ersoy Educational and Training...Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Ege University; Istanbul... and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Coronary Bifurcation Lesion | Left Main Coronary Artery StenosisTurkey (Türkiye)
-
EBI Anti Sepsis BVCR2O B.V.Not yet recruitingCoronary Artery Disease (CAD) | Coronary Artery Bypass Graft Surgery(CABG)United States, Netherlands, Belgium, United Kingdom
-
Mahidol UniversityThe Princess Mantarop Kamalas Foundation, The Nurses' Association of Thailand and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Postoperative Recovery | Coronary Artery Bypass Graft (CABG)Thailand
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
Clinical Trials on Interactive Voice Response
-
Michigan State UniversityNational Cancer Institute (NCI)CompletedMelanoma | Leukemia | Breast Neoplasms | Prostatic Neoplasms | Colorectal NeoplasmsUnited States
-
M.D. Anderson Cancer CenterCompleted
-
University of MichiganCompletedHypertensionHonduras, Mexico
-
M.D. Anderson Cancer CenterAmerican Cancer Society, Inc.Completed
-
M.D. Anderson Cancer CenterCompletedLung CancerUnited States
-
VA Office of Research and DevelopmentCompleted
-
M.D. Anderson Cancer CenterCompletedEsophageal Cancer | Lung CancerUnited States